FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Publicaciones (208) Publicaciones de FERNANDO LÓPEZ-RÍOS MORENO
2024
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
The Lancet Regional Health - Europe, Vol. 38
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
European Urology Focus
-
NTRK gene fusion testing and management in lung cancer
Cancer Treatment Reviews, Vol. 127
-
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists
Histopathology, Vol. 84, Núm. 3, pp. 429-439
-
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
Archives of Pathology and Laboratory Medicine, Vol. 148, Núm. 7, pp. 757-774
-
QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2023
-
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562
-
Caracterización y clasificación molecular del cáncer de pulmón
Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120
-
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward
Expert Opinion on Biological Therapy, Vol. 23, Núm. 5, pp. 407-418
-
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle
Modern Pathology
2022
-
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma
Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 793-805
-
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354
-
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
BMC Cancer, Vol. 22, Núm. 1
-
Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms
Modern Pathology
2021
-
Cellular pathology in the COVID-19 era: A European perspective on maintaining quality and safety
Journal of Clinical Pathology, Vol. 74, Núm. 1, pp. 64-66
-
Erratum: Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients with NTRK Fusion Cancer (Arch Pathol Lab Med (2021) 145: 4 (441–447) DOI: 10.5858/arpa.2020-0042-OA)
Archives of Pathology and Laboratory Medicine